article thumbnail

A spatial approach to understanding drug dynamics using mass spectrometry imaging

Drug Target Review

Targeted drug delivery and therapeutic development MSI offers significant advantages for those developing small molecule therapeutics. 2021, 56 (8), e4717. 2021, 32 (4), 977–988. For instance, Cheng et al. Mass Spectrom. Xie F, Gales T, Ringenberg MA, et al. Release 2022, 352 , 199–210. Mass Spectrom.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Unimodality does not allow for mixing data: cell data, images, molecular data, clinical data records, small molecule descriptors, ADME Tox data, transcriptomic data, text-based drug and disease representations, clinical trial protocols, publications and patent data, etc. Lifescienceleader.com.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Redevelopment of ChEBI

The ChEMBL-og

ChEBI has for the past >20 years provided the biological community with access to definitive small molecule information and data, including accurate representations of often complex chemical structures. Outdated infrastructure Back in 2021, ChEBI's software infrastructure was increasingly fragile.

article thumbnail

Leadership in the Age of Stacks

LifeSciVC

One team might be working on a cell therapy, another on RNA, another on small molecules. The exuberance of 2020–2021 has given way to a more constrained, unpredictable landscape. These organizations rarely follow a single asset path. They run portfolios across multiple programs, modalities, and often geographies.

article thumbnail

Leveraging agonist antibodies to address immunological diseases

Drug Target Review

Nat Rev Immunol 21, 680–686 (2021). Medivation where she led the development and manufacturing organisations for both biologics and small molecule products. Therap Adv Gastroenterol. 2022 Nov 29; 15:17562848221138160. 4 McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future.

article thumbnail

Crinecerfont

New Drug Approvals

2021 Nov 30;186(1):R1-R14. gmol 1 3D model ( JSmol ) Interactive image show SMILES show InChI Prete A, Auchus RJ, Ross RJ: Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. doi: 10.1530/EJE-21-0794.

FDA
article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

It is worth noting that trial ran from 2018 to 2021, before the U.S. Thermo Fisher delivers everything needed for biologics, small molecule and viral vector manufacturing, all the way through validation and regulatory support. Food and Drug Administrations (FDA) diversity and inclusion in clinical trials mandate.